Will Chou

Will Chou

Company: Aruvant

Job title: CEO

Seminars:

The Promise for ARU-1801, a Differentiated Lentiviral Vector Gene Therapy for Sickle Cell Disease 3:00 pm

Introduction to Aruvant’s gene therapies for rare diseases Overview of how ARU-1801 is a differentiated investigational gene therapy for individuals living with severe sickle cell disease A review of recent data from Aruvant’s ongoing MOMENTUM study in individuals with sickle cell diseaseRead more

day: Day Two

Joint Q&A 5:00 pm

Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.